{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:18:19Z","timestamp":1790878699963,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ygyno.2021.06.009","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T12:45:02Z","timestamp":1624452302000},"page":"715-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study"],"prefix":"10.1016","volume":"162","author":[{"given":"Tamar","family":"Safra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barliz","family":"Waissengrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Bernstein-Molho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geula","family":"Klorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Josephy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakefet","family":"Chen-Shtoyerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.06.009_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0010","unstructured":"Cancer Stat Facts: Female Breast Cancer. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER); 2019."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0020","unstructured":"Cancer Stat Facts: Ovarian Cancer. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER); 2019."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0025","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA\u202f: the journal of the American Medical Association."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0090-8258(03)00152-5","article-title":"Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel","volume":"89","author":"Hirsh-Yechezkel","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0040","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.2147\/OTT.S195552","article-title":"Role of Olaparib as maintenance treatment for ovarian Cancer: the evidence to date","volume":"12","author":"Montemorano","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0050","doi-asserted-by":"crossref","unstructured":"T.R. Rebbeck, T. Friebel, H.T. Lynch, S.L. Neuhausen, L. van 't Veer, J.E. Garber, et al., Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 22 (2004) 1055\u20131062.","DOI":"10.1200\/JCO.2004.04.188"},{"key":"10.1016\/j.ygyno.2021.06.009_bb0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","article-title":"Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review","volume":"212","author":"Ludwig","year":"2016","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0060","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA : the journal of the American Medical Association."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0065","doi-asserted-by":"crossref","unstructured":"K.E. Lewis, K.H. Lu, A.M. Klimczak, S.C. Mok, Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers (Basel). 10 (2018).","DOI":"10.3390\/cancers10020057"},{"key":"10.1016\/j.ygyno.2021.06.009_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jnci\/djy182","article-title":"Risk-reducing oophorectomy and breast Cancer risk across the Spectrum of familial risk","volume":"111","author":"Terry","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0075","doi-asserted-by":"crossref","unstructured":"B.A. Heemskerk-Gerritsen, C. Seynaeve, C.J. van Asperen, M.G. Ausems, J.M. Collee, H.C. van Doorn, et al., Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 107 (2015).","DOI":"10.1093\/jnci\/djv033"},{"key":"10.1016\/j.ygyno.2021.06.009_bb0080","doi-asserted-by":"crossref","unstructured":"J. Kotsopoulos, T. Huzarski, J. Gronwald, C.F. Singer, P. Moller, H.T. Lynch, et al., Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 109 (2017).","DOI":"10.1093\/jnci\/djw177"},{"key":"10.1016\/j.ygyno.2021.06.009_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13058-017-0826-5","article-title":"Decision making for breast cancer prevention among women at elevated risk","volume":"19","author":"Padamsee","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0090","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.27842","article-title":"Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer","volume":"119","author":"Domchek","year":"2013","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.27839","article-title":"The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling","volume":"119","author":"Vencken","year":"2013","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0100","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","article-title":"Breast cancer following ovarian cancer in BRCA mutation carriers","volume":"149","author":"Gangi","year":"2014","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2017.02.032","article-title":"Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: is preventive mastectomy warranted?","volume":"145","author":"McGee","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0110","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0115","unstructured":"NCCN. Genetic\/familial high risk assessment: breast and ovarian. Version 2.2017. . NCCN Clinical Practice Guidelines in Oncology. Fort Washington (PA): National Comprehensive Cancer Network; 2016."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.breast.2019.10.012","article-title":"Breast cancer surveillance for BRCA1\/2 mutation carriers - is \"early detection\" early enough?","volume":"49","author":"Bernstein-Molho","year":"2020","journal-title":"Breast."},{"key":"10.1016\/j.ygyno.2021.06.009_bb0125","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1177\/0003134820964208","article-title":"Breast Cancer surveillance following ovarian Cancer in BRCA mutation carriers","volume":"86","author":"Fong","year":"2020","journal-title":"Am. Surg."},{"key":"10.1016\/j.ygyno.2021.06.009_bb5000","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821004893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821004893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:57:27Z","timestamp":1758772647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821004893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0090825821004893"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.06.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}